Is vitamin K supplementation required in patients with cirrhosis?

Vitamin K Supplementation in Cirrhosis: Not Recommended

Vitamin K supplementation is not required or recommended for patients with cirrhosis, as it does not effectively correct INR prolongation or prevent bleeding in this population. 1

Key Evidence from Guidelines

The 2022 EASL Clinical Practice Guidelines explicitly state that vitamin K administration to correct prolonged INR in chronic liver disease is not supported by evidence 1. The guidelines emphasize several critical points:

Why Vitamin K Doesn't Work in Cirrhosis

• Oral and subcutaneous vitamin K do not improve INR in patients with cirrhosis 1
• Studies demonstrate that even single subcutaneous doses fail to modify coagulation parameters 1
• Intravenous vitamin K can transiently correct INR only in cholestatic liver disease, not in cirrhosis from other causes 1
• The prolonged INR in cirrhosis reflects impaired hepatic synthetic function, not vitamin K deficiency 1

Clinical Evidence Against Routine Use

Multiple recent studies confirm the guideline recommendations:

• A 2023 retrospective study of 85 hospitalized cirrhotic patients (76.5% Child-Pugh C) showed absolute INR change of only -0.07 after vitamin K administration, with no difference between oral vs IV routes or single vs multiple doses 2
• A 2020 multicentre study of 370 cirrhotic patients with GI bleeding found no reduction in 30-day rebleeding rates with vitamin K (16.5% rebleeding in vitamin K group vs 5.5% without vitamin K) 3
• A 2016 matched cohort study (n=276) demonstrated that vitamin K administration did not affect INR changes (AOR = 1.17,95%CI: 0.66-2.08, p=0.59) or bleeding events (AOR = 4.90,95%CI: 0.56-43.0, p=0.15) 4

The Exception: Cholestatic Liver Disease

The only scenario where vitamin K may be beneficial is in cholestatic liver disease (e.g., primary biliary cholangitis, primary sclerosing cholangitis, obstructive jaundice), where fat-soluble vitamin malabsorption causes true vitamin K deficiency 1, 5. Even in these cases:

• The effect is transient 1
• IV administration is required for meaningful effect 1
• This represents a fundamentally different mechanism than cirrhosis-related coagulopathy

FDA-Approved Indications

The FDA label for vitamin K lists approved indications including "hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis" 5. Notably, cirrhosis itself is not listed as an indication, and the label warns that "repeated large doses of vitamin K are not warranted in liver disease if the response to initial use of the vitamin is unsatisfactory" 5.

What Actually Matters for Bleeding Risk

The guidelines make clear that:

• INR does not predict bleeding risk in cirrhosis 1
• Studies show no difference in INR between cirrhotic patients who bleed and those who don't 1
• Bleeding in cirrhosis is primarily related to portal hypertension, not coagulation defects 1
• Correction of INR with FFP or vitamin K does not modify thrombin generation in cirrhotic patients 1

Clinical Recommendations

For Spontaneous Bleeding Prevention

• Do not use vitamin K prophylactically 1
• Do not use FFP to correct INR (strong recommendation, 93% agreement) 1
• Focus on managing portal hypertension rather than coagulation parameters 1

For Invasive Procedures

• Correction of prolonged INR with FFP is not recommended to decrease procedure-related bleeding (strong recommendation, 93% agreement) 1
• Laboratory evaluation of hemostasis is generally not indicated to predict post-procedural bleeding 1
• Vitamin K has no established role in pre-procedure preparation 1

Nutritional Supplementation

The guidelines do recommend optimizing other nutritional deficiencies (iron, folic acid, vitamin B6, vitamin B12) in cirrhotic patients, especially before invasive procedures 1. However, vitamin K is conspicuously absent from this recommendation.

Common Pitfalls to Avoid

1. Don't reflexively give vitamin K for elevated INR in cirrhosis - this is outdated practice not supported by evidence
2. Don't assume INR predicts bleeding risk - it doesn't in cirrhosis
3. Don't delay necessary procedures to "correct" INR with vitamin K - it won't work
4. Don't confuse cirrhosis with cholestatic disease - only the latter may respond to vitamin K

The One Nuanced Exception

A 2024 study on cefoperazone/sulbactam use in cirrhosis suggested prophylactic vitamin K1 may reduce antibiotic-induced coagulation disorders 6. However, this addresses drug-induced vitamin K antagonism (cefoperazone has an N-methylthiotetrazole side chain), not cirrhosis-related coagulopathy itself - a distinct clinical scenario.

Bottom line: Stop giving vitamin K routinely to cirrhotic patients. It doesn't work, wastes resources, and perpetuates the misconception that correcting INR prevents bleeding in cirrhosis.